You are here

  • Home
  • Archive
  • Volume 10, Issue 7
  • Efficacy and safety of anti-PD1 monotherapy or in combination with ipilimumab after BRAF/MEK inhibitors in patients with BRAF mutant metastatic melanoma

Article metrics

Article menu
Clinical/translational cancer immunotherapy
Original research
Efficacy and safety of anti-PD1 monotherapy or in combination with ipilimumab after BRAF/MEK inhibitors in patients with BRAF mutant metastatic melanoma

 

Online download statistics by month:

Online download statistics by month: July 2022 to December 2025

AbstractFullPdf
Jul 2022765789288
Aug 202244145284
Sep 202226327274
Oct 202230130464
Nov 202220020142
Dec 202217818144
Jan 202316216246
Feb 202312212458
Mar 2023717330
Apr 2023575725
May 2023676835
Jun 2023656522
Jul 2023424226
Aug 2023353522
Sep 2023232314
Oct 2023333327
Nov 2023444423
Dec 2023313121
Jan 2024343520
Feb 2024606026
Mar 2024656656
Apr 2024525242
May 2024424223
Jun 2024646325
Jul 2024969748
Aug 2024434414
Sep 2024565637
Oct 2024696923
Nov 2024596022
Dec 2024626323
Jan 2025838338
Feb 2025373718
Mar 2025535334
Apr 202510210456
May 2025454545
Jun 2025313226
Jul 2025110
Aug 2025110
Dec 2025110
Total395640201521